1. ICH guideline M7(R1) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, 2017.
2. International Agency for Research on Cancer (IARC), IARC Monographs on the Evaluation of the Carcinogenic Risk of Humans, Vol. 77, Some Industrial Chemicals, Lyon, France IARC Press, 2000.
3. FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity (July 13, 2018), 2018. 〈https://www.fda.gov/news-events/press-announcements/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity〉, (Accessed 26 June 2024.).
4. The contamination of valsartan and other sartans, Part 2: untargeted screening reveals contamination with amides additionally to known nitrosamine impurities;Scherf-Clavel;J. Pharm. Biomed. Anal.,2019
5. NDMA impurity in valsartan and other pharmaceutical products: analytical methods for the determination of N-nitrosamines;Parr;J. Pharm. Biomed. Anal.,2019